Drug companies defrauded Medicare of millions
Charatan, F.
Bmj 323(7317): 828
2001
ISSN/ISBN: 0959-8138 PMID: 11597964 Document Number: 535903
Document emailed within 1 workday
Related Documents
Bisset, K. 1997: Private vs. public. In Australia, health insurance companies compete with the country's free, high-quality Medicare program Modern Healthcare 27(44): I10 I12Le Texier, E. 2004: Des millions de sans-papiers mexicains aux Etats-Unis: vers une régularisation ? - Millions of undocumented Mexicans in the United States : towards a regularization ? Hommes and Migrations (1987) (1247): 68-74
1995: Des millions de travailleurs en quête de protection sociale - Millions of workers in search of social protection Travail (Geneve) (11): 22-24
Chren, M.M.; Landefeld, C.S. 1991: Doctors, drug companies and gifts Rhode Island Medical Journal 74(12): 603-610
Charatan, F. 2001: Doctors say they are not influenced by drug companies' promotions Bmj 322(7294): 1081
2011: Targeting drug companies' bottom line Prescrire International 20(112): 25
Yamey, G. 2001: Pen "amnesty" for doctors who shun drug companies Bmj 322(7278): 69
Heimoff, S. 2000: Disease management. Getting out from under drug companies' shadows Managed Care 9(3): 39-40; 42-43
2012: Key opinion leaders: used as a marketing tool by drug companies Prescrire International 21(128): 163-165
Safran, D.Gelb.; Wilson, I.B.; Rogers, W.H.; Montgomery, J.E.; Chang, H. 2002: Primary care quality in the Medicare Program: comparing the performance of Medicare health maintenance organizations and traditional fee-for-service medicare Archives of Internal Medicine 162(7): 757-765
1994: For U.S. drug companies' products sold in developing countries, labeling is often inadequate American Journal of Hospital Pharmacy 51(7): 875-876
2014: Most profitable U.S. drug and biologic companies. Ranked by 2013 profit margin Modern healthcare Suppl: 30
2010: Drug companies monitor prescriptions and sales to fine-tune their marketing strategies Prescrire International 19(107): 140-141
Carlson, J. 2011: Data-mining law struck down. Supreme court sides with drug companies in Vermont ruling Modern Healthcare 41(26): 8-9
Bilodeau, Aèle.; Filion, G.; Labrie, L.; Bouteiller, D.; Perreault, M. 2005: Is it possible to sustain health promotion programs in private companies? The case of four Quebec private companies of blue collar workers Canadian Journal of Public Health 96(2): 114-120
Sharma, D.C. 2004: India pressed to relax rules on clinical trials. Drug companies claim changes are essential, but critics fear Indian patients will become guinea pigs Lancet 363(9420): 1528-1529
Wilensky, G.R. 2006: Implementing the Medicare drug benefit--the first 90 days Healthcare Financial Management: Journal of the Healthcare Financial Management Association 60(6): 42-43
Cundiff, D.K. 2003: Medicare prescription drug benefit realities Medgenmed: Medscape General Medicine 5(4): 28
Penna, P. 2004: Outcomes research in the Medicare drug benefit Managed Care Interface 17(1): 19-20
SoRelle, R. 2000: Medicare prescription drug battle heats up Circulation 101(22): E9050-E9051